News | August 08, 2007

Nuclear Oncology Medical Care First in Illinois to Install AccuBoost

August 8, 2007 - Nuclear Oncology Medical Care, DuPage Oncology Center in Winfield, IL, is the first cancer center in the state to install and use the AccuBoost System for image-guided treatment of breast cancer.

The AccuBoost’s first patient in Illinois is 76-year old Mrs. G. Miller who will receive the site-specific radiation treatment for breast cancer in sessions performed over eight days. The treatment is designed to deliver focused radiation to the lumpectomy cavity while minimizing the unintended exposure to the heart and lungs.

"This noninvasive, real-time image-guided treatment ensures better targeting of the lumpectomy cavity and makes it possible to see what you treat and treat what you see," said DuPage Oncology Center Radiation Oncologist, Dr. Dennis Galinsky.

Dr. Anantha Murthy, Associate Professor of Radiation Oncology at Rush Medical College and DuPage Oncology Center said, "When I saw this system at the recent American Brachytherapy Society meeting, I knew we needed to make it available to our patients. Targeting the boost dose has always been a challenge; this system solves the problem."

"Typically delivered prior to the main external beam breast irradiation, AccuBoost is presently used as a replacement for the electron boost that normally would follow the standard treatment," said DuPage Oncology Center's Chief of Medical Physics, Dr. Mohamed Hamadeh. "The breast is immobilized and imaged in a manner similar to mammography allowing a special applicator to be positioned, delivering the radiation with far better accuracy."

For more information: www.AccuBoost.com

Related Content

advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...
brain SPECT imaging, dementia, depression, Daniel G. Amen

Representative brain SPECT scans in a patient with Alzheimer's dementia showing substantially reduced brain blood flow in the temporal and parietal lobes compared to a person with depression with mild decreased frontal lobe blood flow. Image courtesy of Amen Clinics.

News | SPECT Imaging | February 22, 2017
February 22, 2017 — Does a patient have depression or a cognitive disorder (CD) such as Alzheimer's disease or both?
News | Nuclear Imaging | December 12, 2016
Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected...
xSPECT Quant technology, SPECT/CT, Symbia Intevo, Siemens Healthineers, RSNA 2016
News | SPECT Imaging | December 06, 2016
December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
News | Radiopharmaceuticals and Tracers | September 06, 2016
Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging | July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
Overlay Init